These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 26923732)

  • 1. Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
    Moors T; Paciotti S; Chiasserini D; Calabresi P; Parnetti L; Beccari T; van de Berg WD
    Mov Disord; 2016 Jun; 31(6):791-801. PubMed ID: 26923732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Parnetti L; Paciotti S; Eusebi P; Dardis A; Zampieri S; Chiasserini D; Tasegian A; Tambasco N; Bembi B; Calabresi P; Beccari T
    Mov Disord; 2017 Oct; 32(10):1423-1431. PubMed ID: 28843015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.
    Parnetti L; Chiasserini D; Persichetti E; Eusebi P; Varghese S; Qureshi MM; Dardis A; Deganuto M; De Carlo C; Castrioto A; Balducci C; Paciotti S; Tambasco N; Bembi B; Bonanni L; Onofrj M; Rossi A; Beccari T; El-Agnaf O; Calabresi P
    Mov Disord; 2014 Jul; 29(8):1019-27. PubMed ID: 24436092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
    Blanz J; Saftig P
    J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
    Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Singleton A; Shaw LM; Trojanowski JQ; Frasier M; Simuni T; Iranzo A; Oertel W; Siderowf A; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Marek K; Galasko D;
    Mov Disord; 2019 Sep; 34(9):1354-1364. PubMed ID: 31361367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Majbour NK; Vaikath NN; Eusebi P; Chiasserini D; Ardah M; Varghese S; Haque ME; Tokuda T; Auinger P; Calabresi P; Parnetti L; El-Agnaf OM
    Mov Disord; 2016 Oct; 31(10):1535-1542. PubMed ID: 27548849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
    Bellomo G; Paciotti S; Gatticchi L; Parnetti L
    Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
    Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.
    Paciotti S; Gatticchi L; Beccari T; Parnetti L
    Clin Chim Acta; 2019 Aug; 495():13-24. PubMed ID: 30922855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease.
    Pchelina S; Emelyanov A; Baydakova G; Andoskin P; Senkevich K; Nikolaev M; Miliukhina I; Yakimovskii A; Timofeeva A; Fedotova E; Abramycheva N; Usenko T; Kulabukhova D; Lavrinova A; Kopytova A; Garaeva L; Nuzhnyi E; Illarioshkin S; Zakharova E
    Neurosci Lett; 2017 Jan; 636():70-76. PubMed ID: 27780739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.
    Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG
    J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
    Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
    Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.
    Xicoy H; Peñuelas N; Vila M; Laguna A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31731485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Xilouri M; Brekk OR; Stefanis L
    Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
    Huebecker M; Moloney EB; van der Spoel AC; Priestman DA; Isacson O; Hallett PJ; Platt FM
    Mol Neurodegener; 2019 Nov; 14(1):40. PubMed ID: 31703585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Emerging Role of the Lysosome in Parkinson's Disease.
    Navarro-Romero A; Montpeyó M; Martinez-Vicente M
    Cells; 2020 Nov; 9(11):. PubMed ID: 33147750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.